Novartis : NVS

All Novartis Articles

134 Articles

Paul Ausick | Nov 18, 2014 at 9:10 AM EST

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.

Lee Jackson | Oct 2, 2014 at 8:55 AM EDT

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.

Lee Jackson | Jul 8, 2014 at 10:15 AM EDT

Upcoming Catalysts Could Drive Seven Biotech and Health Care Stocks Higher

ThinkstockBinary events are often the key element in moving a biotech or health care stock higher. Negative binary results or…

Jon C. Ogg | Jun 9, 2014 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: BioMarin, Family Dollar, Lululemon, SunTrust and More

These are the top Wall Street analyst upgrades, downgrades and initiations see on Monday, June 9, 2014. They include BioMarin,…

Trey Thoelcke | May 22, 2014 at 8:20 AM EDT

Why You Buy Big Pharma If the Market Crashes

A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is…

Jon C. Ogg | May 2, 2014 at 8:46 AM EDT

Top Analyst Upgrades and Downgrades: Avanir, Avon, Broadcom, Endo, Oracle, Wynn and More

These are the top analyst upgrades, downgrades and initiations from Wall Street for Friday, May 2, 2014. They include Avanir,…

Paul Ausick | Mar 20, 2014 at 12:10 PM EDT

Akebia, MediWound Post Gains Following IPOs

Mediwound offered 5 million shares in a Thursday IPO at the low end of the expected range. Akebia Therapeutics offered…

Trey Thoelcke | Feb 17, 2014 at 7:05 AM EST

Biotech Buyout Bolsters Novartis Cancer Portfolio

Novartis announced Monday morning that it will acquire privately held startup biotech CoStim Pharmaceuticals. Terms of the deal were not…

Trey Thoelcke | Nov 22, 2013 at 7:00 AM EST

Novartis Announces Share Buybacks and Business Expansion

ThinkstockSpeculation has run hot that Swiss drugmaker Novartis A.G. (NYSE: NVS) would announced further restructuring at its investor day in…

Trey Thoelcke | Nov 11, 2013 at 7:30 AM EST

Shire, Novartis Deals: Pharmaceutical Shakeups Continue

ThinkstockThe wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ:…

Lee Jackson | Sep 16, 2013 at 8:45 AM EDT

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the…

Trey Thoelcke | Sep 13, 2013 at 8:50 AM EDT

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

ThinkstockWith yields on 10-year Treasury bonds up nearly 1.5% since early May and briefly touching 3.0% last week, the impact…

Paul Ausick | Jul 2, 2013 at 7:35 AM EDT

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a…

Jon C. Ogg | Jun 6, 2013 at 8:00 AM EDT

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

ThinkstockAs the pharmaceuticals industry looks toward restructuring and separation of undervalued assets, Jefferies analysts have prepared a highly proprietary sum…

Jon C. Ogg | Jan 17, 2013 at 8:29 AM EST

Jefferies Top Global Pharmaceutical Stock Picks for 2013 (JEF, ABBV, NVS, SNY, PFE)

ThinkstockAfter a strong year of relative performance for pharmaceutical stocks in 2012, the analysts at Jefferies Group Inc. (NYSE: JEF)…

1 … 4 5 6 7 8 9

Novartis : NVS

All Novartis Articles

Companies Spending the Most on R&D

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

Upcoming Catalysts Could Drive Seven Biotech and Health Care Stocks Higher

Top Analyst Upgrades and Downgrades: BioMarin, Family Dollar, Lululemon, SunTrust and More

Why You Buy Big Pharma If the Market Crashes

Top Analyst Upgrades and Downgrades: Avanir, Avon, Broadcom, Endo, Oracle, Wynn and More

Akebia, MediWound Post Gains Following IPOs

Biotech Buyout Bolsters Novartis Cancer Portfolio

Novartis Announces Share Buybacks and Business Expansion

Shire, Novartis Deals: Pharmaceutical Shakeups Continue

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

Jefferies Top Global Pharmaceutical Stock Picks for 2013 (JEF, ABBV, NVS, SNY, PFE)

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Novartis : NVS

All Novartis Articles

Companies Spending the Most on R&D

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

Upcoming Catalysts Could Drive Seven Biotech and Health Care Stocks Higher

Top Analyst Upgrades and Downgrades: BioMarin, Family Dollar, Lululemon, SunTrust and More

Why You Buy Big Pharma If the Market Crashes

Top Analyst Upgrades and Downgrades: Avanir, Avon, Broadcom, Endo, Oracle, Wynn and More

Akebia, MediWound Post Gains Following IPOs

Biotech Buyout Bolsters Novartis Cancer Portfolio

Novartis Announces Share Buybacks and Business Expansion

Shire, Novartis Deals: Pharmaceutical Shakeups Continue

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

Jefferies Top Global Pharmaceutical Stock Picks for 2013 (JEF, ABBV, NVS, SNY, PFE)

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s